Please assess the completion status of the following clinical trial:

Trial Title: Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is a female ≥18 years old.~2. Presents with a diagnosis of Stage IIIC ovarian cancer.~3. Presents with high-grade serous carcinoma.~4. Has one of the following:~   1. Visible residual tumor ≤1 cm after primary tumor debulking surgery.~  2. Three cycles of neoadjuvant chemotherapy and complete resection after interval tumor debulking surgery.~  3. Three cycles of neoadjuvant chemotherapy and visible residual tumor ≤1 cm after interval tumor debulking surgery.~5. ECOG performance status of 0 or 1.~6. Is willing to comply with required follow-up study visits.~7. Is willing and able to provide written informed consent.~Exclusion Criteria:~1. Has a life expectancy of \<3 months.~2. Is pregnant, as confirmed through a blood test prior to any study procedure, planning on becoming pregnant during the study, or is lactating.~3. Will be receiving intraperitoneal chemotherapy.~4. Has undergone prior treatment with abdominal and/or pelvic radiotherapy.~5. Has significant active concurrent medical illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~6. Presence of central nervous system or cerebral metastases.~7. Recurrent ovarian cancer.~8. Complete resection with no residual tumor after primary tumor debulking surgery.~9. Suboptimal resection with \>1 cm residual tumor after primary or interval tumor debulking surgery.~10. Is simultaneously enrolled in another investigational study.~11. Has a history of cancer within 5 years other than in-situ uterine cervix cancer or non-melanoma skin cancer.~12. Has a known hypersensitivity to carboplatin or paclitaxel.~13. Is concurrently using other antineoplastic agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M-Trap (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).